Wednesday, July 25, 2007
Indian Pharma Companies for Inorganic Route to Billion-dollar Club
BlogOut provides regular, global outsourcing updates. See BlogOut Directory for the complete list of categories
See also outsourcing updates for related categories: Medicine & Healthcare, India
Indian Pharma Companies for Inorganic Route to Billion-dollar Club
Tinesh Bhasin, DNA India
MUMBAI: Indian pharma firms are now eyeing inorganic growth overseas as they inch towards the elite billion dollar club. They see acquisitions contributing 20-40% of revenues, in the process assisting them to to breach the billion dollar mark.
Companies such as Lupin are looking for a distribution company is US, and aims to achieve $1 billion in sales in two years. This target is difficult to achieve without any acquisitions.
Four many more domestic pharmaceutical companies, including Nicholas Piramal, Cadila, Aurobindo and Wockhardt, too, are marching towards the billion dollar club. Analysts feel that though achievable, these companies need acquisitions to breach that mark, says this report @ DNA India
Click on the labels below for more posts on those categories
See also outsourcing updates for related categories: Medicine & Healthcare, India
Indian Pharma Companies for Inorganic Route to Billion-dollar Club
Tinesh Bhasin, DNA India
MUMBAI: Indian pharma firms are now eyeing inorganic growth overseas as they inch towards the elite billion dollar club. They see acquisitions contributing 20-40% of revenues, in the process assisting them to to breach the billion dollar mark.
Companies such as Lupin are looking for a distribution company is US, and aims to achieve $1 billion in sales in two years. This target is difficult to achieve without any acquisitions.
Four many more domestic pharmaceutical companies, including Nicholas Piramal, Cadila, Aurobindo and Wockhardt, too, are marching towards the billion dollar club. Analysts feel that though achievable, these companies need acquisitions to breach that mark, says this report @ DNA India
Click on the labels below for more posts on those categories
Labels: acquisitions-pharma, competitive-advantage, pharma-india
PermaLink - Indian Pharma Companies for Inorganic Route to Billion-dollar Club posted by Ecacofonix : 8:17 AM
0 Comments
European Pharma Industry in Good Shape but Acquisitions Pose Risk - S&P
BlogOut provides regular, global outsourcing updates. See BlogOut Directory for the complete list of categories
See also outsourcing updates for related categories: Medicine & Healthcare, Europe
European Pharma Industry in Good Shape but Acquisitions Pose Risk - S&P
20 Jul 2007
MUMBAI (Thomson Financial) - Most main European pharmaceutical companies are in good shape, but acquisitions continue to be the most important reason for a potential deterioration of a company's credit quality, S&P's Ratings Services said.
For example, S&P's placement of AstraZeneca PLC's ratings on negative watch was caused by the company's debt-financed acquisition of MedImmune.
In a report, the agency noted that first-quarter revenue growth of these companies continued to beat underlying global market growth, estimated at 6-7 pct.
Read the full report from here @ Forbes
Click on the labels below for more posts on those categories
See also outsourcing updates for related categories: Medicine & Healthcare, Europe
European Pharma Industry in Good Shape but Acquisitions Pose Risk - S&P
20 Jul 2007
MUMBAI (Thomson Financial) - Most main European pharmaceutical companies are in good shape, but acquisitions continue to be the most important reason for a potential deterioration of a company's credit quality, S&P's Ratings Services said.
For example, S&P's placement of AstraZeneca PLC's ratings on negative watch was caused by the company's debt-financed acquisition of MedImmune.
In a report, the agency noted that first-quarter revenue growth of these companies continued to beat underlying global market growth, estimated at 6-7 pct.
Read the full report from here @ Forbes
Click on the labels below for more posts on those categories
Labels: acquisitions-pharma, competitive-advantage, europe, pharma-europe
PermaLink - European Pharma Industry in Good Shape but Acquisitions Pose Risk - S&P posted by Ecacofonix : 8:10 AM
0 Comments
Thursday, March 8, 2007
Actavis gains new contract manufacturing capabilities in India
Actavis gains new contract manufacturing capabilities in India
By Kirsty Barnes
15 February 2007
Actavis has waded further into India and picked up new contract manufacturing capabilities along the way with the purchase of a division of Sanmar Specialty Chemicals (SSCL).
The acquired active pharmaceutical ingredients (API) division mainly conducts API contract manufacturing for both the Indian and international pharmaceutical markets.
Read more from this in Pharma Technologist report
By Kirsty Barnes
15 February 2007
Actavis has waded further into India and picked up new contract manufacturing capabilities along the way with the purchase of a division of Sanmar Specialty Chemicals (SSCL).
The acquired active pharmaceutical ingredients (API) division mainly conducts API contract manufacturing for both the Indian and international pharmaceutical markets.
Read more from this in Pharma Technologist report
Labels: acquisitions, acquisitions-pharma, active-pharmaceutical-ingredients, contract-manufacturing, contract-manufacturing-india, contract-manufacturing-pharma, pharma, pharma-india
PermaLink - Actavis gains new contract manufacturing capabilities in India posted by Ecacofonix : 3:14 AM
0 Comments
Subscribe to Posts [Atom]